Boost radiation for HPV throat cancer with shorter treatment
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies whether adding a precise “extra boost” to radiation can work as well as (or better than) standard radiation for HPV-related oropharynx cancer, while keeping the overall treatment shorter. It may help improve tumor control while aiming for manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign an informed consent form
- Your cancer biopsy shows squamous cell cancer in the oropharynx (throat area)
- Your tumor tests positive for HPV (either p16 staining or HPV in-situ test)
- Your cancer stage is T1 to T3 with N1 and M0 (stage I–II), and the main tumor is under 30 cc
- Your overall health is good enough for treatment (ECOG 0 to 2) and you plan curative chemoradiation
- You are not pregnant (for people who could become pregnant, pregnancy test must be negative)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This trial tests whether giving less radiation after surgery is safe and effective for people with early-stage HPV-related throat cancer. It aims to reduce side effects while still controlling the cancer.
This trial tests whether giving less radiation (while using standard chemotherapy) can treat HPV-related throat cancer effectively. It may help reduce radiation exposure while still controlling the cancer.
This trial studies a lower-intensity (less aggressive) course of radiation therapy after curative surgery for HPV-related tonsil or base-of-tongue cancer. The goal is to see if patients can still be treated successfully while reducing side effects from radiation.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.